Chongqing Lummy Pharmaceutical Salute del bilancio

Salute finanziaria criteri di controllo 5/6

Chongqing Lummy Pharmaceutical ha un patrimonio netto totale di CN¥2.1B e un debito totale di CN¥394.4M, che porta il suo rapporto debito/patrimonio netto a 18.7%. Le sue attività totali e le sue passività totali sono rispettivamente CN¥3.0B e CN¥929.3M.

Informazioni chiave

18.7%

Rapporto debito/patrimonio netto

CN¥394.41m

Debito

Indice di copertura degli interessi	n/a
Contanti	CN¥1.09b
Patrimonio netto	CN¥2.11b
Totale passività	CN¥929.27m
Totale attività	CN¥3.04b

Aggiornamenti recenti sulla salute finanziaria

Nessun aggiornamento

Recent updates

Subdued Growth No Barrier To Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006) With Shares Advancing 32%

Nov 15

We Think Chongqing Lummy Pharmaceutical's (SZSE:300006) Healthy Earnings Might Be Conservative

Oct 29

Revenues Not Telling The Story For Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006) After Shares Rise 36%

Oct 01

What Chongqing Lummy Pharmaceutical Co., Ltd.'s (SZSE:300006) 36% Share Price Gain Is Not Telling You

Oct 01

Risks To Shareholder Returns Are Elevated At These Prices For Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006)

Feb 27

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( CN¥1.8B ) di 300006 superano le sue passività a breve termine ( CN¥781.9M ).

Passività a lungo termine: Le attività a breve termine di 300006 ( CN¥1.8B ) superano le sue passività a lungo termine ( CN¥147.4M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: 300006 ha più liquidità del suo debito totale.

Riduzione del debito: Il rapporto debito/patrimonio netto di 300006 si è ridotto da 66% a 18.7% negli ultimi 5 anni.

Copertura del debito: Il debito di 300006 è ben coperto dal flusso di cassa operativo ( 56.7% ).

Copertura degli interessi: Dati insufficienti per determinare se i pagamenti degli interessi sul debito di 300006 siano ben coperti dall'EBIT.

Chongqing Lummy Pharmaceutical Salute del bilancio

Salute finanziaria criteri di controllo 5/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Subdued Growth No Barrier To Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006) With Shares Advancing 32%

We Think Chongqing Lummy Pharmaceutical's (SZSE:300006) Healthy Earnings Might Be Conservative

Third quarter 2024 earnings released: CN¥0.025 loss per share (vs CN¥0 in 3Q 2023)

Revenues Not Telling The Story For Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006) After Shares Rise 36%

What Chongqing Lummy Pharmaceutical Co., Ltd.'s (SZSE:300006) 36% Share Price Gain Is Not Telling You

Chongqing Lummy Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 23, 2024

New minor risk - Share price stability

Investor sentiment improves as stock rises 19%

Second quarter 2024 earnings released: EPS: CN¥0.006 (vs CN¥0.048 loss in 2Q 2023)

Chongqing Lummy Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 24, 2024

First quarter 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.003 loss in 1Q 2023)

First quarter 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.003 loss in 1Q 2023)

First quarter 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.003 loss in 1Q 2023)

First quarter 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.003 loss in 1Q 2023)

First quarter 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.003 loss in 1Q 2023)

First quarter 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.003 loss in 1Q 2023)

First quarter 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.003 loss in 1Q 2023)

Chongqing Lummy Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 24, 2024

Chongqing Lummy Pharmaceutical Co., Ltd., Annual General Meeting, Apr 12, 2024

Full year 2023 earnings released: CN¥0.008 loss per share (vs CN¥0.065 loss in FY 2022)

Risks To Shareholder Returns Are Elevated At These Prices For Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006)

Chongqing Lummy Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Mar 23, 2024

Less than half of directors are independent

Third quarter 2023 earnings released: EPS: CN¥0 (vs CN¥0.011 in 3Q 2022)

Second quarter 2023 earnings released: CN¥0.048 loss per share (vs CN¥0.021 loss in 2Q 2022)

Full year 2022 earnings released: CN¥0.065 loss per share (vs CN¥0.10 loss in FY 2021)

Third quarter 2022 earnings released: EPS: CN¥0.011 (vs CN¥0.012 loss in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.021 loss per share (vs CN¥0.017 loss in 2Q 2021)

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Chongqing Lummy Pharmaceutical Co., Ltd., Annual General Meeting, Apr 15, 2022

Chongqing Lummy Pharmaceutical Co., Ltd., Annual General Meeting, Apr 15, 2022

Full year 2021 earnings: EPS and revenues miss analyst expectations

First quarter 2021 earnings released: EPS CN¥0.055 (vs CN¥0.01 loss in 1Q 2020)

Full year 2020 earnings released: CN¥0.40 loss per share (vs CN¥0.19 loss in FY 2019)

Changzhou Lummy Qingfeng Pharmaceutical Industry Investment Center (Limited Partnership) agreed to acquire 35% Chengdu Medicom Medical Information Systems Co., Ltd from Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006) for approximately CNY 200 million.

Chongqing Lummy Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 31, 2021

New 90-day low: CN¥6.65

Hangzhou Bulaisen Pharmaceutical Technology Co., Ltd. signed a share transfer agreement to acquire Sichuan Hezheng Pharmaceutical Co., Ltd. from Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006) for approximately CNY 170 million.

New 90-day low: CN¥7.08

New 90-day high: CN¥8.54

New 90-day high: CN¥8.21

Third quarter earnings released

Chongqing Lummy Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 28, 2020

First half earnings released

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane